ABT: who owns it, and who’s predicted to buy next
Abbott Laboratories · Health Care · on the Prior Moves forward board for 2026-09-30 at rank #39. Research, not investment advice.
Predicted to buy next quarter
3 tracked investors rank ABT in the top tenth of their own model’s candidates for 2026-09-30, strongest first. This is a forecast about a later filing, not a confirmation that anyone has bought the security or a recommendation to do so.
- Engaged
- Larry Robbins · Glenview
- Paul Singer · Elliott
Strongest ranked investor signal: Engaged. No calibrated purchase probability is shown.
Currently disclosed holders
From the most recent 13F books we track, 1 investor discloses a position in ABT (weight = share of that investor’s US equity book). A 13F can be up to 45 days stale.
| Investor | Book weight |
|---|---|
| Southeastern | 4.0% |
Mutual fund and ETF holders
475 US mutual funds and ETFs from 212 fund families reported a position in ABT for the quarter ending 2026-06-30. Against their own report a quarter earlier, 195 raised shares, 35 opened a new position, 181 cut and 86 sold out. Source: SEC Form N-PORT, which funds file about 60 days after quarter end. Share counts, not trades: a change can reflect fund inflows rather than a decision about ABT.
| Fund family | Funds | Share of fund-held shares |
|---|---|---|
| Vanguard Index Funds | 4 | 40.7% |
| Ishares Trust | 15 | 15.1% |
| Select Sector Spdr Trust | 1 | 4.2% |
| Investment Co Of America | 1 | 3.5% |
| Vanguard Institutional Index Funds | 2 | 3.5% |
| Spdr Series Trust | 16 | 3.2% |
| Franklin Mutual Series Funds | 4 | 1.8% |
| T. Rowe Price Value Fund, Inc. | 1 | 1.7% |
The predicted next buys, fresh disclosures, and the week’s catalysts. One email a week. Honest numbers, never advice.
See the full ranked board on top picks, how the PriorScore is built on how it works, the honest edge numbers on methodology, and the running accuracy on the prediction leaderboard. Forward quarter 2026-09-30, data as of 2026-10-17. Research, not investment advice, see the disclaimer.